- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00326105
Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders (PEARL)
24. marts 2009 opdateret af: AstraZeneca
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo- Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major Depressive Disorder With Inadequate Response to an Antidepressant Treatment (PEARL STUDY)
The purpose of this study is to evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in patients with MDD with inadequate response to an antidepressant treatment.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
450
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater
- Research Site
-
-
California
-
El Centro, California, Forenede Stater
- Research Site
-
Irvine, California, Forenede Stater
- Research Site
-
Oceanside, California, Forenede Stater
- Research Site
-
San Diego, California, Forenede Stater
- Research Site
-
-
Colorado
-
Pueblo, Colorado, Forenede Stater
- Research Site
-
-
Florida
-
Coral Springs, Florida, Forenede Stater
- Research Site
-
Deland, Florida, Forenede Stater
- Research Site
-
Gainsville, Florida, Forenede Stater
- Research Site
-
Hialeah, Florida, Forenede Stater
- Research Site
-
Jacksonville, Florida, Forenede Stater
- Research Site
-
Miami, Florida, Forenede Stater
- Research Site
-
Orlando, Florida, Forenede Stater
- Research Site
-
West Palm Beach, Florida, Forenede Stater
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater
- Research Site
-
Roswell, Georgia, Forenede Stater
- Research Site
-
-
Illinois
-
Hoffman Estates, Illinois, Forenede Stater
- Research Site
-
Naperville, Illinois, Forenede Stater
- Research Site
-
Oak Brook, Illinois, Forenede Stater
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater
- Research Site
-
Lafayette, Indiana, Forenede Stater
- Research Site
-
Valparaiso, Indiana, Forenede Stater
- Research Site
-
-
Kansas
-
Prairie Village, Kansas, Forenede Stater
- Research Site
-
Wichita, Kansas, Forenede Stater
- Research Site
-
-
Louisiana
-
Shreveport, Louisiana, Forenede Stater
- Research Site
-
-
Maryland
-
Glen Burnie, Maryland, Forenede Stater
- Research Site
-
-
Massachusetts
-
Braintree, Massachusetts, Forenede Stater
- Research Site
-
Springfield, Massachusetts, Forenede Stater
- Research Site
-
-
Michigan
-
Clinton Township, Michigan, Forenede Stater
- Research Site
-
Kalamazoo, Michigan, Forenede Stater
- Research Site
-
Royal Oak, Michigan, Forenede Stater
- Research Site
-
-
Missouri
-
St Charles, Missouri, Forenede Stater
- Research Site
-
St. Louis, Missouri, Forenede Stater
- Research Site
-
-
New Jersey
-
Cherry Hill, New Jersey, Forenede Stater
- Research Site
-
Clementon, New Jersey, Forenede Stater
- Research Site
-
-
New York
-
Cedarhurst, New York, Forenede Stater
- Research Site
-
New York, New York, Forenede Stater
- Research Site
-
Olean, New York, Forenede Stater
- Research Site
-
Rochester, New York, Forenede Stater
- Research Site
-
Staten Island, New York, Forenede Stater
- Research Site
-
-
Ohio
-
Beechwood, Ohio, Forenede Stater
- Research Site
-
Toledo, Ohio, Forenede Stater
- Research Site
-
-
Oklahoma
-
Norman, Oklahoma, Forenede Stater
- Research Site
-
Oklahoma City, Oklahoma, Forenede Stater
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater
- Research Site
-
-
Rhode Island
-
Lincoln, Rhode Island, Forenede Stater
- Research Site
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater
- Research Site
-
-
Tennessee
-
Memphis, Tennessee, Forenede Stater
- Research Site
-
-
Texas
-
Friendswood, Texas, Forenede Stater
- Research Site
-
Houston, Texas, Forenede Stater
- Research Site
-
San Antonio, Texas, Forenede Stater
- Research Site
-
Wichita Falls, Texas, Forenede Stater
- Research Site
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater
- Research Site
-
-
Virginia
-
Arlington, Virginia, Forenede Stater
- Research Site
-
Richmond, Virginia, Forenede Stater
- Research Site
-
-
Washington
-
Bellevue, Washington, Forenede Stater
- Research Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Patient is able to provide written informed consent before beginning any study related procedures
- Patient has a documented clinical diagnosis of major depressive disorder
- Patient is able to understand and comply with the requirements of the study, as judged by a study investigator
Exclusion Criteria:
- Patients with a history of non-compliance as judged by the study investigator
- Patients with a known lack of response to previous treatment with quetiapine
- Patients who have participated in a clinical trial within 4 weeks of randomization
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
---|
To evaluate the efficacy of quetiapine SR in combination with an antidepressant versus an antidepressant alone in MDD patients with inadequate response to an antidepressant treatment as assessed by the change from randomization to week 6 in the MADRS
|
Sekundære resultatmål
Resultatmål |
---|
To evaluate if quetiapine SR in combination with an antidepressant improves health-related quality of life of patients with MDD, compared to an antidepressant alone
|
To evaluate if quetiapine SR in combination with an antidepressant reduces anxiety symptoms in patients with MDD, compared to an antidepressant alone
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- McIntyre RS, Gorwood P, Thase ME, Liss C, Desai D, Chen J, Bauer M. Early Symptom Improvement as a Predictor of Response to Extended Release Quetiapine in Major Depressive Disorder. J Clin Psychopharmacol. 2015 Dec;35(6):706-10. doi: 10.1097/JCP.0000000000000416.
- Weisler R, Montgomery SA, Earley WR, Szamosi J, Eriksson H. Extended release quetiapine fumarate in patients with major depressive disorder: suicidality data from acute and maintenance studies. J Clin Psychiatry. 2014 May;75(5):520-7. doi: 10.4088/JCP.13m08624.
- Weisler R, McIntyre RS, Bauer M. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy. Expert Rev Neurother. 2013 Nov;13(11):1183-200. doi: 10.1586/14737175.2013.846519.
- Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, Earley WR, Eriksson H. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014 Jan;29(1):16-25. doi: 10.1097/YIC.0000000000000011.
- Clayton AH, Locklear JC, Svedsater H, McIntyre RS. Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate. CNS Spectr. 2014 Apr;19(2):182-96. doi: 10.1017/S1092852913000631. Epub 2013 Sep 25.
- Bauer M, McIntyre RS, Szamosi J, Eriksson H. Evaluation of adjunct extended-release quetiapine fumarate on sleep disturbance and quality in patients with major depressive disorder and an inadequate response to on-going antidepressant therapy. Int J Neuropsychopharmacol. 2013 Sep;16(8):1755-65. doi: 10.1017/S146114571300031X. Epub 2013 May 14.
- Vieta E, Bauer M, Montgomery S, McIntyre RS, Szamosi J, Earley WR, Eriksson H. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2013 Sep 5;150(2):639-43. doi: 10.1016/j.jad.2013.01.052. Epub 2013 Mar 14.
- El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010 Aug;13(7):917-32. doi: 10.1017/S1461145710000015. Epub 2010 Feb 23.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. april 2006
Studieafslutning (Faktiske)
1. juli 2007
Datoer for studieregistrering
Først indsendt
15. maj 2006
Først indsendt, der opfyldte QC-kriterier
15. maj 2006
Først opslået (Skøn)
16. maj 2006
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
25. marts 2009
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
24. marts 2009
Sidst verificeret
1. marts 2009
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Adfærdsmæssige symptomer
- Psykiske lidelser
- Stemningsforstyrrelser
- Depression
- Depressiv lidelse
- Depressiv lidelse, major
- Lægemidlers fysiologiske virkninger
- Depressive midler til centralnervesystemet
- Antipsykotiske midler
- Beroligende midler
- Psykotropiske stoffer
- Antidepressive midler
- Quetiapinfumarat
Andre undersøgelses-id-numre
- D1448C00006
- PEARL
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Større depressiv lidelse
-
Shalvata Mental Health CenterUkendt
-
Neumora Therapeutics, Inc.RekrutteringMajor depressiv episode forbundet med bipolar II lidelseForenede Stater
-
Yonsei UniversityAfsluttet
-
Section for Affective Disorders; Northern Stockholm...Afsluttet
-
Gangnam Severance HospitalAfsluttetMajor Depressive Disorder (MDD)Korea, Republikken
-
Seasons Biotechnology (Taizhou) Co., Ltd.AfsluttetMajor Depressive Disorder (MDD)Indien
-
Repurposed Therapeutics, Inc.Ukendt
-
GlaxoSmithKlineAfsluttetMajor Depressive Disorder (MDD)Forenede Stater
-
AccexibleRekrutteringMajor Depressive Disorder (MDD)Spanien
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Ikke rekrutterer endnuMajor Depressive Disorder (MDD)
Kliniske forsøg med Quetiapinfumarat
-
AstraZenecaAfsluttetManiodepressivForenede Stater
-
AstraZenecaAfsluttet
-
University of Medicine and Dentistry of New JerseyAstraZenecaAfsluttetBorderline personlighedsforstyrrelseForenede Stater
-
Roxane LaboratoriesAfsluttetBehandling af Bipolar I lidelseForenede Stater
-
Roxane LaboratoriesAfsluttetBipolar I lidelseForenede Stater
-
AstraZenecaAfsluttet
-
AstraZenecaAfsluttet
-
AstraZenecaAfsluttet
-
Swiss Federal Institute of TechnologyUniversity of Zurich; University Children's Hospital, Zurich; Jomo Kenyatta...Afsluttet